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Abstract 1 
Background:People with end-stage kidney disease (ESKD) are at greater risk of stroke. We 2 
aimed to compare stroke mortality between the ESKD population and the general population. 3 
 4 
Methods:We included all incident ESKD patients in Australia, 1980-2013 and New Zealand, 5 
1988-2012. The primary cause of death was ascertained using data linkage with national 6 
death registers. We produced standardized mortality ratios (SMR) for stroke deaths, by age, 7 
sex and calendar year. 8 
 9 
Results:We included 60,823 ESKD patients, where 941 stroke deaths occurred over 381,874 10 
person-years. ESKD patients had >3 times the stroke deaths compared to the general 11 
population (SMR:3.4, 95%CI:3.2-3.6), markedly higher in younger people and females. The 12 
greatest excess was in intracerebral haemorrhages (SMR:5.2, 95%CI:4.5-5.9). Excess stroke 13 
deaths in ESKD patients decreased over time, though was still double in 2013 (2013 14 
SMR:2.1, 95%CI:1.5-2.9).  15 
 16 
Conclusions:People with ESKD experience much greater stroke mortality with the greatest 17 
difference for women and younger people.  However, mortality has improved over time.  18 
 19 
  20 
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Introduction 21 
People with end-stage kidney disease (ESKD) are at greater risk of stroke, with stroke-22 
hospitalizations 2-3 times that of the general population [1]. Despite the increased risk of 23 
stroke, how ESKD affects stroke mortality remains unclear. Limited trial data suggests some 24 
interventions are less effective in ESKD patients, where statin therapy and warfarin have little 25 
to no effect on reducing stroke events [2, 3]. We aimed to compare stroke mortality rates for 26 
the ESKD population versus the general population, using a population-based approach. 27 
 28 
Method 29 
Study data are available to qualified researchers from the corresponding author, subject to 30 
study and ethical approvals. 31 
 32 
Participants, data linkage and death outcomes 33 
We used prospective observational data collected in the Australian and New Zealand Dialysis 34 
and Transplant (ANZDATA) Registry, which includes all people with ESKD from initiation 35 
of ESKD treatment. Nationwide summary-level data was used to determine stroke mortality 36 
rates in the general population in Australia and in New Zealand. Both countries provided the 37 
number of deaths by underlying cause of death using ICD-10-AM, sex, 5-year age band and 38 
calendar year.  39 
 40 
We used data linkage of ANZDATA to the national death registers to ascertain date and 41 
cause of death. We linked Australian ESKD patients using probabilistic record linkage and 42 
New Zealand ESKD patients using deterministic record linkage. Due to limited data in the 43 
national death registers, we only included incident ESKD patients in Australia, 1980-2013 44 
and in New Zealand, 1988-2012. 45 
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 46 
Stroke deaths were determined from the underlying cause of death only using ICD-10-AM 47 
codes. All other causes of death were considered as non-stroke deaths.  48 
  49 
Statistical analyses 50 
Patient follow-up was from ESKD treatment date until the earliest date of; death, 31 51 
December 2013 (Australia) or 31 December 2012 (New Zealand). We produced mortality 52 
rates and standardized mortality ratios (SMR). The overall cumulative incidence of stroke 53 
mortality was estimated by summing to time t the Kaplan-Meier estimate of the overall 54 
survival function, S(t-1), multiplied by the subtype hazard at time t. 55 
 56 
Ethical approval was granted from the University of Sydney (Project:2014/917), AIHW 57 
(Ref:EO2015/3/181) and the New Zealand Ministry of Health (Ref:14/NTB/171). 58 
 59 
See Supplemental Methods for further methodological details. 60 
 61 
Results 62 
Patient Characteristics 63 
We included 60,823 incident ESKD patients, where death agreement between ANZDATA 64 
and the national death registry was almost perfect (Kappa statistic: 0.85; Supplementary 65 
Table 1). There were 26,505 (41%) patients still alive and 34,318 (59%) patients had died 66 
(Supplementary Fig.1). There were 941 stroke deaths over 381,874 person-years follow-up, 67 
with median follow-up of 4 years (Supplementary Table 2).  68 
 69 
Deaths 70 
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Of the 941 stroke deaths, there were 259(27%) intracerebral haemorrhages, 90(10%) 71 
intracranial haemorrhages, 108(12%) ischaemic strokes, 68(7%) subarachnoid haemorrhages, 72 
302(32%) unspecified strokes and, 114(12%) transient cerebral ischaemic attacks and related 73 
syndromes. The cumulative incidence of all-cause stroke mortality was 1.4%(95%CI:1.3-74 
1.6%) in females and 1.0%(95%CI:0.9-1.1%) in males at 5 years (Fig.1).  75 
 76 
Stroke mortality rates 77 
Overall, the crude mortality rate for all-cause stroke was 246.4(95%CI:231.2-78 
262.7)/100,000person-years. The all-cause stroke mortality rates showed a clear increasing 79 
trend with age for both sexes (Supplementary Fig.2A). However, there was little evidence of 80 
a trend or sex difference for mortality rates in ischaemic strokes and intracerebral 81 
haemorrhages (Supplementary Fig.2B-2C).  82 
 83 
The all-cause stroke mortality showed a slight decreasing trend in more recent years. The all-84 
cause stroke mortality rate per 100,000 person-years decreased from 245.7(95%CI:132.2-85 
456.7) in 1988 to 194.4(95%CI:146.1-258.8) in 2011. There was little evidence of a 86 
consistent pattern for stroke mortality rates over calendar year for ischaemic strokes or 87 
intracerebral haemorrhages.  88 
 89 
Stroke mortality standardized mortality ratios (SMR) 90 
The all-cause stroke SMR was 3.4(95%CI:3.2-3.6), ischaemic stroke was 3.1(95%CI:2.6-3.7) 91 
and intracerebral haemorrhages was 5.2(95%CI:4.5-5.9). The all-cause stroke SMR were 92 
greater in younger age and for females (Fig.2A; Supplementary Table 3). These SMR 93 
decreased with age, where stroke mortality rates in the ESKD population were comparable to 94 
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the general population when aged>75 years. The SMR for ischaemic strokes and intracerebral 95 
haemorrhages followed a similar trend (Fig.2B-2C; Supplementary Table 3). 96 
 97 
The all-cause stroke SMR decreased over time (Fig.3A). The SMR were highest in 1988-98 
1998, where the SMR reduced from 4.1(95%CI:2.9-5.6) in 1998 to 2.1(95%CI:1.5-2.9) in 99 
2013. Since 2000, the intracerebral haemorrhage SMR have stabilized around 5(2013: 5.2 100 
SMR, 95%CI:3.1-8.8; Fig.3B). Ischaemic stroke SMR were substantially varied prior to 101 
1998, after which SMR were relatively stable at <5 (2013: 1.7 SMR, 95%CI:0.7-4.6; Fig.3C). 102 
 103 
Discussion 104 
Our work represents the largest cohort study to date examining stroke death in people with 105 
ESKD. Over 30 years, in a dual-national comparison, people with ESKD had more than 106 
threefold increased risk of stroke death compared to age and sex-matched people in the 107 
general population, predominantly from haemorrhagic stroke. The relative risk of stroke 108 
death was highest for younger people and females. Although stroke death rates have 109 
decreased rapidly in people with ESKD, the risk of stroke death in 2013 was still double that 110 
of the general population.  111 
 112 
We found stroke deaths were more likely in people with ESKD compared to the general 113 
population, being greater for intracerebral haemorrhage than ischaemic stroke. Admission 114 
stroke severity and post-stroke neurological deterioration increases progressively as estimated 115 
glomerular filtration rate decreases [4]. Preventative interventions may be ineffective in the 116 
ESKD population. Antithrombotic agents in people with ESKD are associated with increased 117 
bleeding and cardiovascular mortality, lacking evidence in reducing stroke incidence [3, 5]. 118 
Stroke thrombolysis in people with CKD is associated with an increased risk of haemorrhagic 119 
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transformation and mortality [6]. ESKD-specific factors may also increase bleeding risk, such 120 
as frequent anticoagulation with heparin (on haemodialysis) and uraemia-induced impaired 121 
platelet function. One study found that 35% of haemorrhagic strokes occurred during or 122 
within 30 minutes after haemodialysis [7]. Dialysis patients are also less likely to be managed 123 
in an acute stroke unit and receive post-stroke care compared to patients without CKD [8].  124 
Secondly, age and sex varied the risk of stroke death in people with ESKD. Younger people 125 
experienced up to 15 times the stroke deaths than expected. This suggests the greatest 126 
potential benefit for stroke interventions is amongst the young [9]. The relative protective 127 
effect of being female seen in the general population for Australia and New Zealand, where 128 
women have 20-30% lower risk of stroke death, is lost in ESKD. Women with ESKD reach 129 
menopause 5 years earlier than people without ESKD and are frequently amenorrheic at 130 
ESKD diagnosis, losing the protective effect of oestrogen earlier than expected [10]. Stroke 131 
prevention strategies may be implemented less often in women and sex differences in the 132 
setting of post-stroke care may exist [11].  133 
 134 
Finally, excess stroke deaths in the ESKD population decreased over time, particularly in 135 
1998-2003. An increased prevalence of kidney transplants which are associated with reduced 136 
cardiovascular risk compared to dialysis, better transplant survival and increased living 137 
kidney donation may all contribute to this reduction in risk [12].  138 
 139 
There are several limitations to our study. The primary cause of death was ascertained from 140 
the national death register only, which does not capture overseas deaths, although typically 141 
people with ESKD are not internationally mobile. Large confidence intervals occurred when 142 
stratum-specific sample sizes or general population mortality rates were low, evident in 143 
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younger age bands and <1997. We were limited to the patient treatment data recorded by 144 
ANZDATA, where the use of primary or secondary stroke prevention drugs is not recorded.  145 
 146 
In conclusion, we found that all-cause stroke deaths were >3 times higher in the ESKD 147 
population than expected. Further research is needed into stroke prevention, treatment and 148 
care provided to ESKD patients, particularly in females and younger ESKD. Future studies 149 
explicitly including people with ESKD is required to evaluate the effectiveness, tolerability 150 
and safety of stroke prevention drugs and treatment. A better understanding of the current use 151 
of stroke prevention and care following stroke in the ESKD population would be useful to 152 
determine whether further improvements are possible. 153 
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SUPPLEMENTAL MATERIAL
Supplemental Methods 
People with ESKD: We used observational patient data collected prospectively in the Australian 
and New Zealand Dialysis and Transplant (ANZDATA) Registry, which includes all people 
treated for ESKD from 1964 in Australia and New Zealand. ANZDATA data collection methods 
and validation have been previously described [1]. Briefly, all dialysis and transplant centres in 
Australia and New Zealand provide data on all people with ESKD from initiation of ESKD 
treatment. People with ESKD included any person who was receiving renal replacement therapy, 
including haemodialysis, peritoneal dialysis and kidney transplant. Patient data is collected via 
web-based data entry or printed survey forms as events occur, and annually, for each ESKD 
patient. The core patient data collected include: demographics (date of birth; sex; racial 
background; body mass index; and smoking status), co-morbidities (diabetes; ischaemic heart 
disease; cerebrovascular disease; coronary artery disease; peripheral artery disease; and 
malignancies) and ESKD history (dialysis modality; data of treatment initiation; and cause of 
ESKD). 
 
General population: We used nationwide summary-level data that was publicly available to 
determine stroke mortality rates in the general population in Australia and New Zealand. In 
Australia, the Australian Bureau of Statistics provides publicly available data on the number of 
deaths by underlying cause of death using ICD-10-AM, sex, 5-year age bands and calendar year. 
In New Zealand, the New Zealand Ministry of Health provides data tables on registered deaths 
occurring in New Zealand, stratified by underlying cause of death using ICD-10-AM, sex, 5-year 
age bands and calendar year. 
 
Data linkage: We used data linkage of ANZDATA to the national death registries to ascertain 
date and causes of death, both underlying and contributing causes. In Australia, the National 
Death Index (NDI) records all deaths from 1980 and is maintained by the Australian Institute of 
Health and Welfare (AIHW). We linked Australian ESKD patients using probabilistic record 
linkage, matching on date of birth, sex and full name. In New Zealand, the Mortality Collection 
(MORT) Database records all deaths from 1988 and is maintained by the New Zealand Ministry 
of Health. We linked New Zealand ESKD patients using deterministic record linkage, matching 
on the national health index (NHI) number. In this analysis, we were restricted to data available 
in the national death registries. Hence, we included all incident ESKD patients in Australia, 
1980-2013 and in New Zealand, 1988-2012. 
 
Data linkage were undertaken by the AIHW, and New Zealand Ministry of Health using best-
practice privacy-preserving protocols. Only de-identified data was provided after data linkage 
was complete.   
 
Death ascertainment and cause of death: ESKD patient deaths were ascertained from the 
national death registries only. Stroke deaths were determined from the declared underlying cause 
of death only, using ICD-10-AM codes. Underlying causes of deaths are defined as the disease 
or condition which initiated the sequence of events that resulted in the patients’ death. Where 
contributory causes of death included stroke, but the underlying cause of death listed another 
cause, an individual was deemed to have died a non-stroke death. Contributing or secondary 
causes of death are all other diseases or conditions that contributed to the death but were not the 
underlying cause. Specifically, all-cause stroke deaths included subarachnoid haemorrhage 
(I60.0-I60.9), intracerebral haemorrhages (I61.0-I61.9), intracranial haemorrhages (I62.0-I62.9), 
ischaemic strokes (I63.0-I63.9), unspecified strokes (I64.0-I64.9) and, transient cerebral 
ischaemic attacks and related syndromes (G45.0-G45.9). Subtype stroke deaths of interest 
included intracerebral haemorrhages and ischaemic strokes. All other causes of death were 
considered as non-stroke deaths. The causes of death were summarized using the leading causes 
of death, modified by AIHW [2]. 
 
Statistical analyses 
Patient follow-up was from ESKD treatment date until the earliest date of; death, 31 December 
2013 (Australian only) or 31 December 2012 (New Zealand only). As probabilistic record 
linkage could lead to a small proportion of incorrect links [3], Australian ESKD patients with 
discordant records were censored at the ANZDATA date of death when the national death 
registry had not captured any death. We used the Kappa statistic to evaluate agreement of fact of 
death [4]. 
 
Crude mortality rates were produced for all-cause and subtype stroke deaths by dividing the 
number of stroke deaths by the total follow-up time where patients were at risk of stroke, by age, 
sex, and calendar year. We used indirect standardization to produce standardized mortality ratios 
(SMR). Briefly, all-cause and subtype stroke crude mortality rates were calculated for the 
general population in Australia and New Zealand, by age, sex and calendar year. For the general 
population, the numerator was considered as the total stroke deaths and the denominator was the 
population total for the given calendar year, sex and 5-year age band. The general population 
stroke mortality rates were then applied to the person-years of follow-up in the ESKD population 
to estimate the expected number of all-cause and subtype stroke deaths. The SMR were then 
estimated as the ratio between the sum of observed deaths and the expected deaths. A test for 
linear trend for age and calendar year were performed on the SMR. 
 
Data were analysed using Stata version 14 (Stata Corporation, College Station, TX, USA). 
 
  
Supplementary Table 1. Agreement for fact of death between ANZDATA and national 
death registries. 
(A) Overall1 
    Death Registry 
Total 
    Dead Alive 
ANZDATA 
Dead 34 206 1 623 35 829 
  (56) (3)   
Alive 2 823 22 171 24 994 
  (5) (36)   
Total 
37 029 23 794 60 823 
    (100) 
(B) Australia2 
    Death Registry 
Total 
    Dead Alive 
ANZDATA 
Dead 28 880 1 106 29 986 
  (56) (2)   
Alive 2 823 18 642 21 465 
  (5) (36)   
Total 
31 703 19 748 51 451 
    (100) 
(C) New Zealand3 
    Death Registry 
Total 
    Dead Alive 
ANZDATA 
Dead 5 326  517 5 843 
  (57) (6)   
Alive  0 3 529 3 529 
  (-) (38)   
Total 
5 326 4 046 9 372 
    (100) 
1Overall agreement for fact of death was 92.7% with Kappa statistic of 0.85 (p-value <0.001). 
2Overall agreement for fact of death was 92.4% with Kappa statistic of 0.84 (p-value <0.001). 
3Overall agreement for fact of death was 94.5% with Kappa statistic of 0.89 (p-value <0.001). 
 
  
Supplementary Table 2. Characteristics of all patients with end-stage kidney disease 
included in the study, stratified by death status. 
Characteristics 
All-cause 
stroke deaths 
Other deaths Alive Total 
n (%)1 n (%)1 n (%)1 n (%)1 
Total, (%) 941 (2)2 33,377 (55)2 26,505 (43)2 60,823 (100) 
                
Age at ESKD diagnosis (years)               
≤29 25 (3) 1,150 (3) 3,913 (15) 5,088 (8) 
30-49 177 (19) 5,399 (16) 8,231 (31) 13,807 (23) 
50-64 329 (35) 11,417 (34) 8,234 (31) 19,980 (33) 
65-74 261 (28) 9,658 (29) 3,923 (15) 13,842 (23) 
≥75 149 (16) 5,753 (17) 2,204 (8) 8,106 (13) 
Median [IQR] 62  
[52, 
71]  
63  
[53, 
72]  
51 
[38, 
63] 
59  
[46, 
69]  
Gender               
Female 472 (50) 13,901 (42) 10,669 (40) 25,042 (41) 
Male 469 (50) 19,476 (58) 15,836 (60) 35,781 (59) 
Year of ESKD               
≤1990 209 (22) 6,269 (19) 1,770 (7) 8,248 (14) 
1991-1999 297 (32) 10,637 (32) 3,819 (14) 14,753 (24) 
2000-2009 382 (41) 14,561 (44) 11,401 (43) 26,344 (43) 
2010-2013 53 (6) 1,910 (6) 9,515 (36) 11,478 (19) 
Country               
Australia 819 (87) 28,173 (84) 22,459 (85) 51,451 (85) 
New Zealand 122 (13) 5,204 (16) 4,046 (15) 9,372 (15) 
Racial background               
Caucasian 737 (78) 26,290 (79) 19,003 (72) 46,030 (76) 
Non-caucasian 204 (22) 7,087 (21) 7,502 (28) 14,793 (24) 
Comorbidities at ESKD               
Cerebrovascular disease 246 (26) 5,393 (16) 2,037 (8) 7,676 (13) 
Diabetes 313 (33) 12,863 (39) 8,541 (32) 21,717 (36) 
Coronary artery disease 372 (40) 14,310 (43) 6,103 (23) 20,785 (34) 
Peripheral artery disease 252 (27) 9,487 (28) 3,634 (14) 13,373 (22) 
Previous malignancy 208 (22) 9,707 (29) 5,873 (22) 15,788 (26) 
Smoking status               
Current/Former 413 (44) 16,081 (48) 11,895 (45) 28,389 (47) 
Never 345 (37) 11,955 (36) 13,561 (51) 25,861 (43) 
Unknown 183 (19) 5,341 (16) 1,049 (4) 6,573 (11) 
Cause of renal failure               
Diabetes 249 (26) 9,925 (30) 6,735 (25) 16,909 (28) 
Hypertension/renal artery disease 169 (18) 4,763 (14) 2,332 (9) 7,264 (12) 
Glomerulonephritis/IgA nephropathy 211 (22) 7,626 (23) 8,795 (33) 16,632 (27) 
Polycystic kidney disease 71 (8) 1,623 (5) 2,309 (9) 4,003 (7) 
Other 241 (26) 9,440 (28) 6,334 (24) 16,015 (26) 
                
Transplanted at beginning of study 4 (<0.5) 151 (<0.5) 1,494 (6) 1,649 (3) 
Transplanted during study 154 (16) 4,997 (15) 11,051 (42) 16,202 (27) 
 
1Column percentage; 2Row percentage. 
Supplementary Table 3. Standardized mortality ratios (SMR) in the end-stage kidney 
disease population compared to the general population for all-cause stroke and stroke 
subtype, by sex and age. 
  O E SMR(95% CI) O E SMR(95% CI) 
Age at death(years) 30-49 50-64 
Male          
Any stroke death 55 3.0 18.5(14.2, 24.0) 149 17.4 8.6(7.3, 10.1) 
Intracerebral haemorrhage 25 0.9 27.9(18.8, 41.3) 61 5.0 12.1(9.4, 15.6) 
Ischaemic stroke 3 0.3 10.5(3.4, 32.6) 13 2.4 5.4(3.1, 9.3) 
Unspecified stroke 8 0.2 46.1(23.1, 92.3) 27 2.8 9.6(6.6, 14.0) 
Female          
Any stroke death 53 1.9 28.3(21.6, 37.1) 143 10.0 14.4(12.2, 16.9) 
Intracerebral haemorrhage 24 0.4 58.3(39.1, 87.0) 50 2.7 18.6(14.1, 24.6) 
Ischaemic stroke 8 0.1 55.7(27.9, 111.4) 15 0.8 18.3(11.1, 30.4) 
Unspecified stroke 5 0.1 58.2(24.2, 139.8) 34 1.1 31.0(22.1, 43.4) 
Age at death (years) 65-74 75+ 
Male             
Any stroke death 151 40.6 3.7(3.2, 4.4) 112 110.5 1.0(0.8, 1.2) 
Intracerebral haemorrhage 29 9.3 3.1(2.2, 4.5) 19 16.5 1.2(0.7, 1.8) 
Ischaemic stroke 23 5.6 4.1(2.7, 6.2) 10 14.4 0.7(0.4, 1.3) 
Unspecified stroke 51 12.5 4.1(3.1, 5.4) 58 63.0 0.9(0.7, 1.2) 
Female           
Any stroke death 146 23.5 6.2(5.3, 7.3) 127 71.0 1.8(1.5, 2.1) 
Intracerebral haemorrhage 30 5.3 5.7(4.0, 8.2) 19 9.9 1.9(1.2, 3.0) 
Ischaemic stroke 21 2.7 7.7(5.0, 11.8) 14 8.6 1.6(1.0, 2.7) 
Unspecified stroke 55 6.8 8.1(6.2, 10.5) 64 42.9 1.5(1.2, 1.9) 
O: Observed; E: Expected; SMR: Standardized mortality ratio; 95%CI:95% Confidence interval 
Supplementary Figure 1. Flowchart of data linkage process between the end-stage kidney 
disease population and the national death registries in Australia and New Zealand.   
End-stage kidney disease population, 1980-2013  
(n=60,823) 
Deaths (n=38,652) 
• Given by National Registry and ANZDATA (n=34,206; AU=28,880, NZ=5,326) 
• Given by National Registry only (n=2,823; AU=2,823, NZ=0) 
• Given by ANZDATA only (n=1,623; AU=1,106, NZ=517) 
Australia, 1980-2013  
(n=51,451) 
New Zealand, 1988-2012  
(n=9,372) 
Mortality collection database, 1988-2012  National Death Index, 1980-2013  
Probabilistic 
linkage 
Deterministic 
linkage 
5,326 deaths from 
9,372 ESKD patients 
31,703 deaths from 
51,451 ESKD patients  
1,623 deaths from 
ANZDATA only  
Supplementary Figure 2. Crude mortality rates in people with end-stage kidney disease, 
stratified by age and sex, in: (A) all-cause strokes; (B) intracerebral haemorrhages; and, 
(C) ischaemic strokes. 
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